Unique characteristics discriminate germ cell tumors (GCTs) from other solid malignancies. Patients are predominantly young men between 15 and 40 years with few comorbidities (if any); tumors are particularly sensitive to platinum-based chemotherapy; and a cure is still possible with salvage approaches in patients with progression after first-line chemotherapy. Curative salvage strategies involve conventional-dose chemotherapy (CDCT) or, alternatively, high-dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT), which-in contrast to virtually all other types of solid tumors-can be highly effective. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] A retrospective analysis of 1594 patients undergoing initial salvage chemotherapy found better outcomes for patients who received sequential HDCT cycles compared with single-cycle HDCT. 11, 12 Additional reports have demonstrated excellent outcomes with regimens consisting of both two or three HDCT cycles. 2, 10, 11, 13, 14 When comparing single versus tandem autotransplants for relapsed GCT patients in an intention-to-treat analysis, no differences in 5-year PFS and overall survival (OS) were reported between two carboplatin/etoposide (CE)-based HDCT/ASCT cycles versus treatment with a single cycle of HDCT. 15 However, the optimum number of CE-HDCT cycles with ASCT for relapsed GCT patients remains to be established in prospective studies.
Swiss transplant centers consistently follow a salvage strategy with three CE-HDCT cycles for relapsing GCT patients; however, the third cycle has occasionally been omitted owing to reasons including toxicities, poor condition, patient refusal, physicianrelated decisions or progressive disease. As significant toxicity is associated with repetitive HDCT/ASCT cycles, it is of obvious interest whether subgroups of patients can be identified who enjoy comparable benefit from HDCT treatment with fewer than three cycles. In this retrospective analysis, we investigated whether patients have a specific survival benefit from a third cycle of CE-HDCT depending on whether they achieved a complete second remission after the first CE-HDCT/ASCT cycle (early CR2).
We were able to analyze all consecutive patients with a first relapse of GCT undergoing initial salvage CE-based HDCT with subsequent ASCT between 1997 and 2014 in Switzerland. The cohort also included marker-negative relapsing GCT as well as primary mediastinal GCT. The data have prospectively been collected in the national ASCT registry, and 173 patients were identified. The clinical characteristics of the patients are summarized in Supplementary Table 1. A total of 154 (89.0%) patients received HDCT conditioning comprising CE and 19 (11.0%) patients had an additional third compound (CE+). Initial mobilization regimens consisted of the VIP (etoposide, ifosfamide and cisplatin) or TIP regimen (paclitaxel, ifosfamide and cisplatin), followed by three cycles of 1500 mg/m 2 carboplatin and 1500 mg/m 2 etoposide (CE-HDCT) given in three divided doses over 3 days, and followed by reinfusion of autologous peripheral blood progenitor cells. Cycles were repeated at intervals of 21 days or more when clinically indicated.
Our survival analysis is based on the intention-to-treat principle as Swiss centers consistently follow a salvage strategy aiming at three HDCT cycles. The 5-year PFS and 5-year OS of the entire cohort (n = 173) were 51.0% and 52.8%, respectively (Table 1 ; Supplementary Figures 1A and 1B) , which compares favorably to the CIBMTR cohort 15 with a 5-year OS of 35% vs 42% for 2 versus 1 HDCT, and a 5-year PFS of 34% vs 38%, respectively. The outcome in our cohort differed between seminomas (n = 35) and non-seminoma GCT (n = 138), with the 5-year PFS being 67.9% and 46.3% (P = 0.0362), respectively, and the 5-year OS rates were 70.2% and 48.0% (P = 0.0505), respectively ( Table 1 ; Supplementary Figures 1E and 1F) .
A considerable number of patients did not receive the full program of three planned cycles. Whereas 70 patients (40.5%) indeed underwent 3 HDCTs with ASCT, 60 patients (34.7%) had 2 and 43 patients (24.9%) were given only 1 HDCT cycle. Reasons for giving fewer than three cycles included toxicities or infections during the previous HDCT in 15 patients (14.6%), poor general condition in 19 patients (18.5%), death within the first 100 days after the preceding HDCT in 8 patients (7.8%), and progressive or refractory disease in 28 patients (27.2%); 20 patients (19.4%) were considered to have a favorable risk profile and additional HDCT cycles were not considered to be necessary by the treating physicians, 4 (4.1%) patients refused additional HDCT treatment and the reason remained unclear in 9 patients (8.7%).
We observed that the survival rates differed between patients receiving different numbers of HDCT/ASCT. The PFS rates for one, two or three cycles of HDCT were 38.1%, 50.9% and 57.9%, respectively, and the OS rates were 40.5%, 52.4% and 59.1%, respectively (Table 1 ; Supplementary Figures 1C and 1D) . The initial hypothesis of our analysis was to investigate whether a third HDCT can be safely omitted in patients achieving a CR after a first HDCT cycle (early CR2). Our data suggest that the opposite is true. Patients with early CR2 appeared to particularly benefit from the three HDCT cycles, as no patient achieving CR2 after cycle 1 ultimately relapsed after cycle 3 (n = 11) in our cohort, whereas one-third of GCT in CR2 after cycle 1 relapsed if treated with only Abbreviations: 3-nCR = patients not achieving a CR after one HDCT and receiving a total of three HDCT; early CR = CR after the first HDCT; HDCT = high-dose chemotherapy; nCR = failure to achieve a CR after the first HDCT; NSGCT = non-seminoma germ cell tumor; OS = overall survival.
two cycles (n = 19). The 5-year PFS were 100 and 67.5% (P = 0.0415), and the 5-year OS were 100 and 62.1% (P = 0.0358; Table 1 ; Figures 1a and b) . To adjust for covariates, a Cox regression analysis was performed (depicted in Supplementary Table 2 ) for early CR patients. Because of the lack of events among patients with early CR and three HDCTs (3-CR), the effect of three HDCT cycles compared with two cycles could not be estimated. The (global) P-values based on the likelihood ratio test were P = 0.050 for PFS and P = 0.054 for OS. Similarly, we analyzed the effects of 3 (3-nCR (patients not achieving a CR after one HDCT and receiving a total of 3 HDCTs); 59 patients) compared with 2 (2-nCR; 41 patients) HDCT cycles in patients not achieving early CR. The 5-year PFS were 49.6% and 43.5% (P = 0.4277), and the 5-year OS were 52.1% and 48.0% (P = 0.9322), respectively (Figures 1c and d; Supplementary Table  3 ). In conclusion, no survival benefit from a third HDCT cycle could be demonstrated in patients not achieving early CR2.
A number of issues arise from our findings. Apparently, conserved chemosensitivity to CE chemotherapy as demonstrated by achievement of CR after one HDCT cycle, after BEP (bleomycin, etoposide, cisplatin)-based first-line treatment, is associated with favorable outcome in relapsing GCT patients. Consequently, our data indicate that such patients may particularly benefit from three HDCT cycles. Even when acknowledging the inevitable limitations of a retrospective analysis, the 5-year OS of 100% for relapsing GCT patients with early CR and receiving three HDCT cycles remains remarkable and identifies a subgroup with excellent curative potential. Such excellent prognosis, however, seems to be achieved only on the condition of having applied multiple HDCT/ASCT cycles, as the survival rates of early CR patients receiving only a single HDCT/ASCT were poor (5-year PFS and OS of 25.0% (Table 1) ). Future research is needed to elucidate the factors predicting achievement of early CR after a single HDCT/ASCT cycle.
A total of 173 relapsing GCT patients received a total of 373 CE-based HDCTs with ASCT in our cohort. We observed a total of eight deaths within the first 100 days after ASCT, with six deaths after HDCT 1 and two deaths after HDCT 2, whereas no patient died owing to toxicities and/or infections associated with HDCT cycle 3. Thus, the treatment related mortality (TRM) within 100 days after ASCT was 4.6%, and it was 2.1% per single HDCT cycle. As such, it is considerably lower than the TRM rate of 9% in the randomized European IT-94 study, 13 and also below the CIBMTR series with a 1-year TRM of 10% for patients in the single transplant cohort and 3% in the tandem cohort. 15 The optimum salvage chemotherapy strategy (CDCT versus HDCT) for GCT patients relapsing after first-line chemotherapy remains an area of ongoing controversy. A prospective multicenter trial comparing initial salvage HDCT and CDCT is currently in the final stages of initiation (TIGER study). Presumably, this study will help to better assess the initial salvage approach in relapsing GCT patients, but this study is neither designed to identify the optimum number of HDCT cycles nor to define subgroups of relapsing GCT patients benefiting from specific numbers of HDCT cycles.
Consequently, prospective data from adequately powered randomized trials are still lacking to define the optimal number of HDCT cycles in relapsing GCT patients. Our data indicate that HDCT has curative potential in a significant proportion of GCT patients relapsing after the first-line chemotherapy. They further suggest-although acknowledging the limitations of a retrospective study design-that GCT patients achieving CR2 after a single HDCT cycle may particularly benefit from three HDCT cycles, with 5-year PFS and OS rates of 100%. Thus, a prospective trial in relapsing GCT patients addressing the question of the optimum number of HDCT (two vs three) and stratifying patients in early CR2 versus no CR2 after a first HDCT seems warranted.
